A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA), E6010, GRADUALLY INCREASES CORONARY BLOOD-FLOW AFTER THROMBOLYSIS COMPARED WITH NATIVE T-PA, UROKINASE AND BALLOON CATHETER OCCLUSION-REPERFUSION

In a canine copper coil-induced coronary thrombosis model, the differe nces in frequency of reperfusion arrhythmias (premature ventricular co mplexes: PVC) and mortality rate after thrombolysis by intravenous bol us injection of a novel modified tissue-type plasminogen activator (t- PA), E6010, and by continuous intravenous infusion of native t-PA or u rokinase were evaluated. Rapid coronary occlusion and reperfusion were produced with a balloon catheter in another group of dogs, and the fi ndings were compared with those in the thrombolysis groups. Reperfusio n occurred gradually after the administration of E6010, but was signif icantly more rapid after administration of native t-PA and urokinase ( P < 0.05). PVC were observed more frequently in native t-PA, urokinase and balloon occlusion-reperfusion groups than in the E6010 group. The mortality rate due to ventricular fibrillation was 0.0% in the E6010 group, 50.0% in the native t-PA and balloon occlusion-reperfusion grou ps, and 33.3% in the urokinase group. These results suggest that the m ore gradual reperfusion of the coronary artery at an earlier period af ter drug administration led to the lower frequency of reperfusion arrh ythmias and low mortality rate in the E6010 group than in the native t -PA, urokinase and balloon occlusion-reperfusion groups.